CLARIVATE PLC — Form 10-Q
Filed November 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 42/100
What the filing says
Michael Easton promoted to EVP & CFO (effective Aug 8, 2026) with $600k base salary, $750k promotion equity grant (50% RSUs vesting over 3 years, 50% PSUs), and $2M annual equity target starting March 2027. Concurrently, Henry Levy (President, Life Sciences & Healthcare) separated upon sale of that division to Janus Buyer LP (Altaris); Levy received $1.85M severance (18 months base + bonus + COBRA) if terminated without Cause within 6 months post-closing, with all RSUs vesting at Closing and PSUs cancelled.
Why this rating
Executive succession is routine; $750k promotion grant + $1.85M severance are material individual packages (~0.2% of $1.3B market cap each) but segment divestiture is significant structural change requiring more context on Life Sciences revenue/profit.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.